CYTKCytokinetics, Incorporated

$8B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+145.3% YoY

Gross Profit

-$321M-1737.2% margin

Operating Income

-$536M-2902.7% margin

Net Income

-$590M-3191.1% margin

EPS (Diluted)

$-5.26

Cash Flow

Operating Cash Flow

-$396M

Free Cash Flow

-$400M

Stock-Based Comp.

$98M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.5B

Stockholders' Equity

-$135M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$8M	+145.3%
Gross Profit	-$321M	-$323M	+0.5%
Operating Income	-$536M	-$496M	-8.1%
Net Income	-$590M	-$526M	-12.0%

CYTK FY 2024 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena